Related Experiment Video

Updated: Dec 9, 2025

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.7K

Discovery of Covalent MKK4/7 Dual Inhibitor

Jie Jiang1, Baishan Jiang1, Zhixiang He1

  • 1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA.

Cell Chemical Biology
|September 11, 2020
PubMed

Insights

Researchers developed BSJ-04-122, a dual inhibitor targeting MKK4/7 kinases involved in cancer. This covalent inhibitor shows promise, especially when combined with JNK inhibitors for treating triple-negative breast cancer.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Mitogen-activated protein kinase kinase 4 and 7 (MKK4/7) kinases regulate the MAPK signaling pathway.
  • Overexpression of MKK4/7 is linked to tumorigenesis and aggressiveness in various cancers, including breast, prostate, lung, and leukemia.
  • MKK4/7 kinases represent potential therapeutic targets for cancer inhibitor development.

Purpose of the Study:

  • To discover, develop, and validate a novel dual inhibitor targeting MKK4/7 kinases.
  • To assess the selectivity and cellular activity of the developed inhibitor.
  • To evaluate the therapeutic potential of dual MKK4/7 inhibition, particularly in combination with JNK inhibitors.

Main Methods:

  • Discovery and development of a dual MKK4/7 inhibitor, BSJ-04-122.
  • Biochemical and cellular assays to assess kinome selectivity and target engagement.
  • Evaluation of downstream signaling effects and antiproliferative activity in cancer cell lines.
  • Combination studies with a selective covalent JNK inhibitor.

Main Results:

  • BSJ-04-122 was identified as a dual MKK4/7 inhibitor with covalent targeting of a conserved cysteine residue.
  • The inhibitor demonstrated excellent kinome selectivity and potent cellular target engagement.
  • BSJ-04-122 induced robust, target-specific downstream effects.
  • Combination therapy with a JNK inhibitor enhanced antiproliferative activity against triple-negative breast cancer cells.

Conclusions:

  • BSJ-04-122 serves as a valuable pharmacological probe for studying MKK4/7 kinases.
  • Covalent targeting is a validated strategy for developing inhibitors against MKK4/7.
  • The findings support further exploration of MKK4/7 inhibitors for cancer therapy, particularly in combination approaches.
Keywords:
MKK4/7breast cancersmall-molecule kinase inhibitortarget therapy

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
433
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K